2025 Financial Guidance
To advance our strategy and expand our leadership in Fabry and Pompe disease, our financial guidance for 2025 is as follows:
| Total Revenue Growth1 | 17% to 24% |
| Galafold Revenue Growth1 | 10% to 15% |
| Pombiliti + Opfolda Growth1 | 65% to 85% |
| Gross Margin | Mid 80% |
| Non-GAAP Operating Expenses4 | $350M to $370M |
| GAAP Net Income | Positive during H2 2025 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.